Monoclonal Antibodies in Chronic Lymphocytic Leukemia
Lindsay Hladnik,(1) PharmD, BCOP, Kristan Augustin,(2) PharmD, BCOP, and Christopher Arp,(3) PharmD
(1)Washington University in Saint Louis School of Medicine, Department of Medicine, Saint Louis, Missouri; (2)Barnes-Jewish Hospital, Department of Pharmacy, Saint Louis, Missouri; (3)Levine Cancer Institute—Carolinas HealthCare System, Department of Pharmacy, Charlotte, North Carolina
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Lindsay Hladnik, PharmD, BCOP, Washington University Infusion Center Pharmacy, 4921 Parkview Place Suite 7F, St. Louis, MO 63110. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2017;8:29–53 |
© 2017 Harborside™
Monoclonal antibodies that target CD20 and CD52 have been evaluated in the setting of chronic lymphocytic leukemia over the past 2 decades. Incorporating these agents into chemotherapy regimens has improved disease control, making chemoimmunotherapy standard first-line treatment. Further understanding of these agents is imperative for providing good medical care by the advanced practitioner. This review will focus on the development of monoclonal antibodies, as well as describe the efficacy and safety data, administration recommendations, and select safety and monitoring parameters for rituximab, ofatumumab, obinutuzumab, and alemtuzumab.
For access to the full length article, please sign in